Before you sell to, join or invest in NeuroEM Therapeutics, Inc.
MentionFox check on NeuroEM Therapeutics, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/neuroem-therapeutics-inc-form-d-25000001
Check NeuroEM Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about NeuroEM Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
NeuroEM Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-04-23.
NeuroEM Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 23, 2025. The filing reports $1.95M sold. Its industry group is Other Health Care. It names Chuck Papageorgiou (Chief Executive Officer), Jonathan Gordon (Director), Mitch Larimore (Director) (SEC Form D, April 23, 2025).
Is this your company?
Sell to companies like NeuroEM Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-04-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NeuroEM Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind NeuroEM Therapeutics, Inc., from the filings we hold.
Other Health Care raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when NeuroEM Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NeuroEM Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch NeuroEM Therapeutics, Inc. →Get the full cited report on NeuroEM Therapeutics, Inc.
What the filing shows about NeuroEM Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NeuroEM Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives NeuroEM Therapeutics, Inc.'s address as 501 E Kennedy Boulevard, Suite 650, Tampa, FL 33602.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on NeuroEM Therapeutics, Inc. See pricing
NeuroEM Therapeutics, Inc. is a registered filer with the SEC (CIK 2026871) and has filed since 2024-06-17. 2 filings are on record, the latest on 2025-04-23.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
NeuroEM Therapeutics, Inc.'s Form D of 2025-04-23 names Chuck Papageorgiou, Jonathan Gordon and Mitch Larimore as its officers, directors or promoters.
Its new offerings report $2.31M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 863 filings in Other Health Care, totalled by week.
On the filing as: Executive Officer, Director.
Chuck Papageorgiou is named as Chief Executive Officer on the Form D that NeuroEM Therapeutics, Inc. filed with the SEC on 23 April 2025, one of 3 people that filing names.
Jonathan Gordon is named as Director on the Form D that NeuroEM Therapeutics, Inc. filed with the SEC on 23 April 2025, one of 3 people that filing names.
Mitch Larimore is named as Director on the Form D that NeuroEM Therapeutics, Inc. filed with the SEC on 23 April 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-04-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about NeuroEM Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NeuroEM Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NeuroEM Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NeuroEM Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind NeuroEM Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for NeuroEM Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Health care raises in Orlando and Tampa
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/neuroem-therapeutics-inc-form-d-25000001